Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been newly diagnosed with a type of ovarian, peritoneal, or fallopian tube cancer (including a type called carcinosarcoma), and it is believed to be at an advanced stage (Stage III or IV)
- You do not need to start medical treatment or surgery urgently — meaning you can wait at least 2 weeks after diagnosis before beginning treatment
- Your doctors believe you would be a suitable candidate for surgery after completing 2 cycles (rounds) of treatment
- You are willing and able to attend all required visits and understand what taking part in the trial involves
- You are in reasonably good general health, able to carry out daily activities with little or no difficulty (this is measured using a standard health scale called ECOG, scores 0–2)
- You are able to give written consent to participate, following the legal requirements in your country
Who may not be able to join:
- Your liver is not working properly, based on blood test results showing certain liver levels are more than double the normal range
- Your kidneys are not working properly, based on blood test results showing a certain waste product (creatinine) is more than double the normal level
- Your general health is significantly affected, leaving you unable to carry out basic self-care (ECOG score of 3 or higher)
- You are pregnant or currently breastfeeding
- You have had another type of cancer in the last 5 years that could affect your health outlook
- You are unable to swallow tablets
- You are already taking part in another clinical trial for the same condition
- You have another serious medical, mental health, personal, or practical situation that the trial team believes could interfere with your participation or safety (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Viola Heinzelmann-Schwarz, Prof., University Hospital Basel, Head Women's Hospital
Phone: +41 61 3284203
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Focal Outcome Measure (FOM) 1 of pilot study: Proportion of patients for whom the molecular Tumor Board (mTB) considers a different treatment option; FOM 2 of pilot study: Investigation whether the treating oncologist feels better supported by the mTB recommendation considers the additional biological tumor information than by the standard of care where such information is not considered.; FOM 3 of pilot study: Investigation of different treatment decisions by the patient and the treating oncologist.; FOM 4 of pilot study: Preliminary estimate of the actual patient benefit of the intervention...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.